UCART-EgfrVIII

N/A

Report date: 2025/03/20 20:00:06

Base Information

Drug NameUCART-EgfrVIII
Drug Alias Nameallogeneic EGFRvIII chimeric antigen receptor T-cells (Pfizer/Cellectis)
ClassificationBiologics > Antigen > Tumor antigenBiologics > Protein drugs > Recombinant polypeptide
Mechanisms of ActionEpidermal growth factor receptor erbB1 modulators
TargetsEpidermal growth factor receptor erbB1
Therapy Area/IndicationsGlioblastoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesFrance
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesCellectis Sa
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesCellectis SaPfizer Inc
Active IndicationsN/A
Inactive IndicationsGlioblastoma

Other Information

ATC CodeN/A
Related LinksN/A